La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Aurinia Pharmaceuticals Croissance future
Future contrôle des critères 4/6
Aurinia Pharmaceuticals devrait augmenter ses bénéfices et ses revenus de 54.6% et de 17.6% par an respectivement, tandis que le BPA devrait croître de croître de 54.6% par an.
Informations clés
54.6%
Taux de croissance des bénéfices
54.6%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 30.3% |
| Taux de croissance des recettes | 17.6% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 02 Aug 2024 |
Mises à jour récentes de la croissance future
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Recent updates
Aurinia Pharmaceuticals Appears Undervalued
Jul 05We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15Aurinia Pharma Q2 2022 Earnings Preview
Aug 03Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 347 | 111 | 69 | N/A | 5 |
| 12/31/2025 | 279 | 60 | 36 | 72 | 7 |
| 12/31/2024 | 234 | 8 | -5 | 16 | 7 |
| 6/30/2024 | 207 | -50 | -2 | -2 | N/A |
| 3/31/2024 | 191 | -63 | -21 | -20 | N/A |
| 12/31/2023 | 176 | -78 | -34 | -33 | N/A |
| 9/30/2023 | 159 | -77 | -38 | -37 | N/A |
| 6/30/2023 | 160 | -73 | -40 | -39 | N/A |
| 3/31/2023 | 147 | -97 | -65 | -64 | N/A |
| 12/31/2022 | 134 | -108 | -80 | -80 | N/A |
| 9/30/2022 | 129 | -115 | -110 | -116 | N/A |
| 6/30/2022 | 88 | -157 | -141 | -141 | N/A |
| 3/31/2022 | 66 | -168 | -151 | -151 | N/A |
| 12/31/2021 | 46 | -181 | -159 | -158 | N/A |
| 9/30/2021 | 72 | -156 | -138 | -129 | N/A |
| 6/30/2021 | 58 | -148 | -125 | -117 | N/A |
| 3/31/2021 | 51 | -127 | -109 | -101 | N/A |
| 12/31/2020 | 50 | -103 | -77 | -70 | N/A |
| 9/30/2020 | 0 | -129 | -104 | -98 | N/A |
| 6/30/2020 | 0 | -110 | -83 | -82 | N/A |
| 3/31/2020 | 0 | -102 | -73 | -73 | N/A |
| 12/31/2019 | 0 | -88 | -64 | -64 | N/A |
| 9/30/2019 | 0 | -57 | -52 | -52 | N/A |
| 6/30/2019 | 0 | -52 | -51 | -51 | N/A |
| 3/31/2019 | 0 | -61 | -50 | -50 | N/A |
| 12/31/2018 | 0 | -53 | -52 | -52 | N/A |
| 9/30/2018 | 0 | -53 | -47 | -47 | N/A |
| 6/30/2018 | 0 | -48 | -44 | -44 | N/A |
| 3/31/2018 | 0 | -34 | N/A | -46 | N/A |
| 12/31/2017 | 0 | -71 | N/A | -41 | N/A |
| 9/30/2017 | 0 | -76 | N/A | -36 | N/A |
| 6/30/2017 | 0 | -70 | N/A | -32 | N/A |
| 3/31/2017 | 0 | -71 | N/A | -23 | N/A |
| 12/31/2016 | 0 | -23 | N/A | -19 | N/A |
| 9/30/2016 | 0 | -19 | N/A | -19 | N/A |
| 6/30/2016 | 0 | -17 | N/A | -20 | N/A |
| 3/31/2016 | 0 | -14 | N/A | -19 | N/A |
| 12/31/2015 | 0 | -19 | N/A | -18 | N/A |
| 9/30/2015 | 0 | -21 | N/A | -16 | N/A |
| 6/30/2015 | 0 | -13 | N/A | -15 | N/A |
| 3/31/2015 | 0 | -23 | N/A | -16 | N/A |
| 12/31/2014 | 0 | -19 | N/A | -17 | N/A |
| 9/30/2014 | 1 | -15 | N/A | -16 | N/A |
| 6/30/2014 | 1 | -17 | N/A | -14 | N/A |
| 3/31/2014 | 1 | -7 | N/A | -10 | N/A |
| 12/31/2013 | 1 | -3 | N/A | -5 | N/A |
| 9/30/2013 | 0 | -6 | N/A | -3 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: AUPH devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.5% ).
Bénéfices vs marché: AUPH devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: AUPH devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de AUPH ( 17.6% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de AUPH ( 17.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de AUPH devrait être élevé dans 3 ans